The investigators hypothesize that an early molecular profiling, that includes both tissue
and blood-bases analysis, for all NSCLC patients, including stage I-III, will increase
diagnostic efficiency. When molecular profiles are available at an earlier stage of disease,
more patients will benefit from personalized therapy once needed. This will result in both a
better quality of life and outcome.